Login to Your Account


Checking the 'male': FDA testosterone scrutiny puts squeeze on Testim

By Randy Osborne
Staff Writer

Thursday, May 8, 2014
Wider meaning of the 76 percent drop in first-quarter Testim sales related to the prospects for Testopel may not be simple, but Auxilium Pharmaceuticals Inc.'s former (a gel) is apparently on the skids and the latter (a long-acting implantable therapy) falls as well into a suddenly risky field: testosterone replacement therapy (TRT).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription